Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

From Evidence to Practice: Advances in Malignant Pleural Effusion Management
From Evidence to Practice: Advances in Malignant Pleural Effusion Management
Clinician's Roundtable
From Evidence to Practice: Advances in Malignant Pleural Effusion Management
Nicholas Pastis, MD
- Nicholas Pastis, MD
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
CME/CE
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
Solange Peters, MD, PhD
0.50 credits
- Solange Peters, MD, PhD
0.50 credits
Personalized CRC Screening: Applying Real-World Evidence to Test Selection
Personalized CRC Screening: Applying Real-World Evidence to Test Selection
Clinician's Roundtable
Personalized CRC Screening: Applying Real-World Evidence to Test Selection
Brian P. McDonough, MD, FAAFP; David A. Johnson, MD, FACG, FACP
- Brian P. McDonough, MD, FAAFP
- David A. Johnson, MD, FACG, FACP
Exploring Sub-Ablative Radiation to Modulate Immunity in Mesothelioma
Exploring Sub-Ablative Radiation to Modulate Immunity in Mesothelioma
Project Oncology®
Exploring Sub-Ablative Radiation to Modulate Immunity in Mesothelioma
John Cho, MD, PhD, FRCPC
- John Cho, MD, PhD, FRCPC
How Novel Strategies Could Push ALK+ mNSCLC Care Forward
How Novel Strategies Could Push ALK+ mNSCLC Care Forward
Project Oncology®
How Novel Strategies Could Push ALK+ mNSCLC Care Forward
Angel Qin, MD
- Angel Qin, MD
How ALK Vaccines Could Prolong TKI Response in mNSCLC
How ALK Vaccines Could Prolong TKI Response in mNSCLC
Project Oncology®
How ALK Vaccines Could Prolong TKI Response in mNSCLC
Angel Qin, MD
- Angel Qin, MD
Guiding mNSCLC Treatment After ALK-TKI Progression
Guiding mNSCLC Treatment After ALK-TKI Progression
Project Oncology®
Guiding mNSCLC Treatment After ALK-TKI Progression
Alice T. Shaw, MD, PhD
- Alice T. Shaw, MD, PhD
Investigating Unanswered Questions in ALK+ mNSCLC Care
Investigating Unanswered Questions in ALK+ mNSCLC Care
Project Oncology®
Investigating Unanswered Questions in ALK+ mNSCLC Care
Alice T. Shaw, MD, PhD
- Alice T. Shaw, MD, PhD

Medical News

Medical News
AI Endoscopic Depth Assessment for Early Gastric Cancer
10/22/2026
Read more
Medical News
AI Model Predicts Colorectal Cancer Nodal Metastasis
10/16/2026
Read more
Medical News
AI-Assisted RECIST CT Measurement Cut Reading Time
10/16/2026
Read more
Medical News
Urine Methylation Assay Detects Urothelial Cancer Recurrence
10/16/2026
Read more

CME/CE

CME/CE In-Person & Virtual Event
Spotlight on B7-H3 ES-SCLC: Applying ADC Evidence in Real-World Practice
December 5, 2026
Scottsdale, Arizona
1.00 credit
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
MinuteCE®
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 program credits
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
MinuteCE®
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 program credits
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
MinuteCE®
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Virginia Kaklamani, MD, DSc
0.50 program credits
- Virginia Kaklamani, MD, DSc
0.50 program credits

Clinical Practice

From Durability to Discovery: Advances in ALK+ mNSCLC Treatment
From Durability to Discovery: Advances in ALK+ mNSCLC Treatment
Project Oncology®
From Durability to Discovery: Advances in ALK+ mNSCLC Treatment
Angel Qin, MD
- Angel Qin, MD
Patterns of Progression and Resistance in ALK+ mNSCLC
Patterns of Progression and Resistance in ALK+ mNSCLC
Project Oncology®
Patterns of Progression and Resistance in ALK+ mNSCLC
Alice T. Shaw, MD, PhD
- Alice T. Shaw, MD, PhD
Advancing Metastatic Breast Cancer Research Through Philanthropy
Advancing Metastatic Breast Cancer Research Through Philanthropy
On the Frontlines of Metastatic Breast Cancer
Advancing Metastatic Breast Cancer Research Through Philanthropy
Steve Jackson, PharmD; Ted Giovanis, FHFMA, MBA
- Steve Jackson, PharmD
- Ted Giovanis, FHFMA, MBA
Comparing CAR T-Cell Therapies for R/R Multiple Myeloma
Comparing CAR T-Cell Therapies for R/R Multiple Myeloma
Project Oncology®
Comparing CAR T-Cell Therapies for R/R Multiple Myeloma
Charles Turck, PharmD, BCPS, BCCCP; Krina Patel, MD, MSc
- Charles Turck, PharmD, BCPS, BCCCP
- Krina Patel, MD, MSc

Programs

Zidesamtinib for ROS1-Positive Non-Small Cell Lung Cancer
Zidesamtinib for ROS1-Positive Non-Small Cell Lung Cancer
On the Frontlines of Non-Small Cell Lung Cancer
Zidesamtinib for ROS1-Positive Non-Small Cell Lung Cancer
Ryan Quigley; Alexander Drilon, MD
- Ryan Quigley
- Alexander Drilon, MD
Sequencing Decisions in R/R LBCL: CAR T-Cell Therapy and Bispecific Antibodies
Sequencing Decisions in R/R LBCL: CAR T-Cell Therapy and Bispecific Antibodies
Project Oncology®
Sequencing Decisions in R/R LBCL: CAR T-Cell Therapy and Bispecific Antibodies
Steve Jackson, PharmD; Paolo F. Caimi, MD
- Steve Jackson, PharmD
- Paolo F. Caimi, MD
- Narendranath Epperla, MD, MS
Interpreting Oral SERD Trial Data in Metastatic Breast Cancer
Interpreting Oral SERD Trial Data in Metastatic Breast Cancer
On the Frontlines of Metastatic Breast Cancer
Interpreting Oral SERD Trial Data in Metastatic Breast Cancer
Alexandria May, PharmD, BCPS; Donald McDonnell, PhD
- Alexandria May, PharmD, BCPS
- Donald McDonnell, PhD
- Neil M. Iyengar, MD
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Project Oncology®
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Alexandria May, PharmD, BCPS; Shannon Raber, MS, CPNP, RN
- Alexandria May, PharmD, BCPS
- Shannon Raber, MS, CPNP, RN
- Bridget Archambault, MSN, CPNP